Biopreparedness: Developing vaccines for an eradicated disease

Springer Science and Business Media LLC - Tập 9 - Trang 421-430 - 2014
Filippa Lentzos1, Jacob Thorup Cohn2
1Department of Social Science, Health & Medicine, King’s College London, London, UK
2Vice President, Governmental Affairs, Bavarian Nordic A/S, Kvistgård, Denmark

Tóm tắt

The accidental discovery of smallpox vials at the National Institutes of Health earlier this year quickly attracted the attention of the health and security communities. Smallpox was officially eradicated decades ago, and is only supposed to exist in two carefully guarded labs – and the National Institutes of Health isn’t one of them! This interview focuses on a biotech company that has spent the last 10 years developing a vaccine against what has so far been a non-existent disease. It discusses possible avenues for the re-emergence of smallpox, including the impact of developments in synthetic biology, and it gives an inside view on the biodefence industry and its unusual business model.

Tài liệu tham khảo

Gaudioso, J., Brooks, T., Furukawa, K., Lavanchy, D.O., Friedman, D. and Heegaard, E.D. (2011) Likelihood of smallpox recurrence. Journal of Bioterrorism and Biodefense 2: 106. Lentzos, F. (2007) The American biodefence industry: From emergency to nonemergence. Politics and the Life Sciences 26 (1): 15–23.